This technology is an fMRI software toolkit that quantitatively maps cerebral blood volume (CBV) for diagnostics, drug discovery, and drug efficacy testing.
Cerebral blood volume (CBV), a variant of functional magnetic resonance imaging (fMRI), is useful for measuring brain physiology and pathophysiology. Abnormal CBV can be used to predict conversion to advanced forms of psychiatric disease and aid in the diagnosis of neurological disorders. While software tools that utilize structural scans of the brain to generate CBV values exist, they are currently limited to the hippocampal and ventricular regions. As such, there is a need for software tools that map CBV and associated statistics across multiple regions of the brain.
This technology is an fMRI software toolkit that enables semi-automated generation of cerebral blood volume (CBV) maps. Pre- and post-contrast MRI images of the brain are used to output a CBV map in anatomic space. The CBV values calculated by this technology may then be used for applications ranging from clinical diagnostics to monitoring therapeutic efficacy for drug development research. This technology is compatible with existing MRI equipment and can be easily implemented in MRI centers, providing clinicians with an additional method for identifying and monitoring psychiatric and neurological disorders.
This technology has been used to identify and image regions of the brain implicated in preclinical Alzheimer’s disease.
Patents Issued (US 10,198,817, US10,846,858)
IR CU14249
Licensing Contact: Jerry Kokoshka